The seamless integration of dietary plant-derived natural flavonoids and gut microbiota may ameliorate non-alcoholic fatty liver disease: a network pharmacology analysis

References

• Li B, Zhang C, Zhan YT. Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J Gastroenterol Hepatol. 2018;2018:2784537.
   PubMed Web of Science ®Google Scholar
• Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238.
   PubMed Web of Science ®Google Scholar
• Ramakrishna G, Rastogi A, Trehanpati N, et al. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2(3-4):367–383.
   PubMed Web of Science ®Google Scholar
• Bhandari P, Sapra A, Ajmeri MS, et al. Nonalcoholic fatty liver disease: could it be the next medical tsunami? Cureus. 2022;14 (4):1–10
   Web of Science ®Google Scholar
• Giraud J, Saleh M. Host-microbiota interactions in liver inflammation and cancer. Cancers. 2021;13(17):4342.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Wang B. The gut-liver axis in health and disease: the role of gut Microbiota-Derived signals in liver injury and regeneration. Front Immunol. 2021;12:775526.
   PubMed Web of Science ®Google Scholar
• Wang R, Tang R, Li B, et al. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. 2021;18(1):4–17.
   PubMed Web of Science ®Google Scholar
• Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132(12):3577–3584.
   PubMed Web of Science ®Google Scholar
• Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med. 2005;230(3):155–170.
   Web of Science ®Google Scholar
• Murota K, Nakamura Y, Uehara M. Flavonoid metabolism: the interaction of metabolites and gut microbiota. Biosci Biotechnol Biochem. 2018;82(4):600–610.
   PubMed Web of Science ®Google Scholar
• Baky MH, Elshahed MS, Wessjohann LA, et al. Interactions between dietary flavonoids and the gut microbiome: a comprehensive review. Br J Nutr. 2022;128(4):577–591.
   PubMed Web of Science ®Google Scholar
• Ullah A, Munir S, Badshah SL, et al. Important flavonoids and their role as a therapeutic agent. Molecules. 2020;25(22):5243.
   PubMed Web of Science ®Google Scholar
• Zhu X, Bian H, Wang L, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 2019;141:192–204.
   PubMed Web of Science ®Google Scholar
• Park KS, Chong Y, Kim MK. Myricetin: biological activity related to human health. Appl Biol Chem. 2016;59(2):259–269.
   Web of Science ®Google Scholar
• Liu X, Sun R, Li Z, et al. Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. Arch Biochem Biophys. 2021;711:109019.
   PubMed Web of Science ®Google Scholar
• Lin Y, Shi R, Wang X, et al. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8(7):634–646.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang X, Ma L, et al. The network pharmacology integrated with pharmacokinetics to clarify the pharmacological mechanism of absorbed components from viticis fructus extract. J Ethnopharmacol. 2021;278:114336.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wang R, Hua H, et al. Network pharmacology exploration reveals gut microbiota modulation as a common therapeutic mechanism for anti-fatigue effect treated with maca compounds prescription. Nutrients. 2022;14(8):1533.
   PubMed Web of Science ®Google Scholar
• Li S, Fan TP, Jia W, et al. Network pharmacology in traditional Chinese medicine. Evid Based Complement Alternat Med. 2014;2014:138460.
   PubMedGoogle Scholar
• Cheng L, Qi C, Yang H, et al. gutMGene: a comprehensive database for target genes of gut microbes and microbial metabolites. Nucleic Acids Res. 2022;50(D1):D795–D800.
   PubMed Web of Science ®Google Scholar
• Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197–206.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357–W364.
   PubMed Web of Science ®Google Scholar
• Chen X, Li H, Tian L, et al. Analysis of the physicochemical properties of acaricides based on Lipinski’s rule of five. J Comput Biol. 2020;27(9):1397–1406.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605–D612.
   PubMed Web of Science ®Google Scholar
• Raykova D, Kermpatsou D, Malmqvist T, et al. A method for Boolean analysis of protein interactions at a molecular level. Nat Commun. 2022;13(1):4755.
   PubMed Web of Science ®Google Scholar
• Guo L, Cui H, Zhao G, et al. Intramuscular preadipocytes impede differentiation and promote lipid deposition of muscle satellite cells in chickens. BMC Genomics. 2018;19(1):1–14.
   PubMedGoogle Scholar
• Khanal P, Patil BM, Chand J, et al. Anthraquinone derivatives as an immune booster and their therapeutic option against COVID-19. Nat Prod Bioprospect. 2020;10(5):325–335.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Olson AJ. Using autodock for ligand-receptor docking. Curr Protocols Bioinf. 2008;24(1):8.14.1–8.14.40.
   Google Scholar
• Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51(10):2778–2786.
   PubMed Web of Science ®Google Scholar
• Xu X, Yan C, Zou X. Improving binding mode and binding affinity predictions of docking by ligand-based search of protein conformations: evaluation in D3R grand challenge 2015. J Comput Aided Mol Des. 2017;31(8):689–699.
   PubMed Web of Science ®Google Scholar
• Lamothe SM, Guo J, Li W, et al. The human ether-a-go-go-related gene (hERG) potassium channel represents an unusual target for protease-mediated damage. J Biol Chem. 2016;291(39):20387–20401.
   PubMed Web of Science ®Google Scholar
• Mulliner D, Schmidt F, Stolte M, et al. Computational models for human and animal hepatotoxicity with a global application scope. Chem Res Toxicol. 2016;29(5):757–767.
   PubMed Web of Science ®Google Scholar
• Karmaus AL, Mansouri K, To KT, et al. Evaluation of variability across rat acute oral systemic toxicity studies. Toxicol Sci. 2022;188(1):34–47.
   PubMed Web of Science ®Google Scholar
• Madia F, Worth A, Whelan M, et al. Carcinogenicity assessment: addressing the challenges of cancer and chemicals in the environment. Environ Int. 2019;128:417–429.
   PubMed Web of Science ®Google Scholar
• Wang Q, Li X, Yang H, et al. In silico prediction of serious eye irritation or corrosion potential of chemicals. RSC Adv. 2017;7(11):6697–6703.
   Web of Science ®Google Scholar
• Da Silva E, Hickey C, Ellis G, et al. In vitro prediction of clinical signs of respiratory toxicity in rats following inhalation exposure. Curr Res Toxicol. 2021;2:204–209.
   PubMedGoogle Scholar
• Dong J, Wang NN, Yao ZJ, et al. Admetlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminform. 2018;10(1):11.
   PubMedGoogle Scholar
• Lee AY, Park W, Kang TW, et al. Network pharmacology-based prediction of active compounds and molecular targets in Yijin-Tang acting on hyperlipidaemia and atherosclerosis. J Ethnopharmacol. 2018;221:151–159.
   PubMed Web of Science ®Google Scholar
• Oh KK, Adnan M, Cho DH. Network pharmacology-based study to identify the significant pathways of Lentinula edodes against cancer. J Food Biochem. 2022;46(9):e14258.
   PubMed Web of Science ®Google Scholar
• Matsson PR, Kihlberg J. How big is too big for cell permeability? J Med Chem. 2017;60(5):1662–1664.
   PubMed Web of Science ®Google Scholar
• Jiang G, Sun C, Wang X, et al. Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification. Bioengineered. 2022;13(3):5216–5235.
   PubMed Web of Science ®Google Scholar
• Hu Q, Wei S, Wen J, et al. Network pharmacology reveals the multiple mechanisms of Xiaochaihu decoction in the treatment of non-alcoholic fatty liver disease. BioData Min. 2020;13:11.
   PubMed Web of Science ®Google Scholar
• Xu J, Qian D, Jiang S, et al. Application of ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry to determine the metabolites of orientin produced by human intestinal bacteria. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;944:123–127.
   PubMed Web of Science ®Google Scholar
• Tao J, Hua Wang D, Geng Yang C, et al. Biotransformation of luteoloside by a newly isolated human intestinal bacterium using UHPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;991:1–8.
   PubMed Web of Science ®Google Scholar
• Du LY, Zhao M, Xu J, et al. Identification of the metabolites of myricitrin produced by human intestinal bacteria in vitro using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Expert Opin Drug Metab Toxicol. 2014;10(7):921–931.
   PubMed Web of Science ®Google Scholar
• Awaad AK, Kamel MA, Mohamed MM, et al. The role of hepatic transcription factor cAMP response element-binding protein (CREB) during the development of experimental nonalcoholic fatty liver: a biochemical and histomorphometric study. Egyptian Liver Journal. 2020;10:1–13.
   Google Scholar
• Wahlang B, McClain C, Barve S, et al. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal. 2018;49:105–115.
   PubMed Web of Science ®Google Scholar
• Lu Q, Tian X, Wu H, et al. Metabolic changes of hepatocytes in NAFLD. Front Physiol. 2021;12:710420.
   PubMed Web of Science ®Google Scholar
• Hatting M, Tavares CDJ, Sharabi K, et al. Insulin regulation of gluconeogenesis. Ann N Y Acad Sci. 2018;1411(1):21–35.
   PubMed Web of Science ®Google Scholar
• Sangeetha R. Luteolin in the management of type 2 diabetes mellitus. Curr Res Nutr Food Sci. 2019;7(2):393–398.
   Web of Science ®Google Scholar
• Kandasamy N, Ashokkumar N. Myricetin modulates streptozotocin–cadmium induced oxidative stress in long term experimental diabetic nephrotoxic rats. Journal of Functional Foods. 2013;5(3):1466–1477.
   Web of Science ®Google Scholar
• Jeong SH, Lim DS. Insulin receptor substrate 2: a bridge between hippo and AKT pathways. BMB Rep. 2018;51(5):209–210.
   PubMed Web of Science ®Google Scholar
• Ayoub F, Trillo-Alvarez C, Morelli G, et al. Risk factors for hepatic steatosis in adults with cystic fibrosis: similarities to non-alcoholic fatty liver disease. World J Hepatol. 2018;10(1):34–40.
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu Y, Wu M, et al. PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells. J Physiol Biochem. 2017;73(4):583–594.
   PubMed Web of Science ®Google Scholar
• Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26(4):430–443.
   PubMed Web of Science ®Google Scholar
• Brandt A, Hernández-Arriaga A, Kehm R, et al. Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. Sci Rep. 2019;9(1):1–14.
   PubMedGoogle Scholar
• Li L, Liu H, Hu X, et al. Identification of key genes in non-alcoholic fatty liver disease progression based on bioinformatics analysis. Mol Med Rep. 2018;17(6):7708–7720.
   PubMed Web of Science ®Google Scholar
• Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome. 2014;25(9-10):473–486.
   PubMed Web of Science ®Google Scholar
• Hashida R, Nakano D, Yamamura S, et al. Association between activity and brain-derived neurotrophic factor in patients with non-alcoholic fatty liver disease: a data-mining analysis. Life. 2021;11(8):799.
   PubMedGoogle Scholar
• Yang X, Lu D, Zhuo J, et al. The gut-liver axis in immune remodeling: new insight into liver diseases. Int J Biol Sci. 2020;16(13):2357–2366.
   PubMed Web of Science ®Google Scholar
• Sun W, Liu P, Yang B, et al. A network pharmacology approach: inhibition of the NF-κB signaling pathway contributes to the NASH preventative effect of an oroxylum indicum seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats. Phytomedicine. 2021;88:153498.
   PubMed Web of Science ®Google Scholar
• Pan X, Chiwanda Kaminga A, Liu A, et al. Chemokines in non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Front Immunol. 2020;11:1802.
   PubMed Web of Science ®Google Scholar
• Luo D, Jin B, Zhai X, et al. Oxytocin promotes hepatic regeneration in elderly mice. IScience. 2021;24(2):102125.
   PubMed Web of Science ®Google Scholar
• Yan S, Huda N, Khambu B, et al. Relevance of autophagy to fatty liver diseases and potential therapeutic applications. Amino Acids. 2017;49(12):1965–1979.
   PubMed Web of Science ®Google Scholar
• Birkenfeld AL, Shulman GI. Non alcoholic fatty liver disease, hepatic insulin resistance and type 2 diabetes. Hepatology. 2014;59(2):713–723.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Sugimoto K, Inui H, et al. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(13):3777–3785.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Liu H. Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. BMC Endocr Disord. 2022;22(1):1–11.
   PubMed Web of Science ®Google Scholar
• Oh K-K, Gupta H, Ganesan R, et al. A network pharmacology study to determine the integrated application of dietary plant-derived natural flavonoids and gut microbiota against nonalcoholic fatty liver disease. 2022; https://doi.org/10.21203/rs.3.rs-1996432/v1
   Google Scholar